Hohl Benjamin
Hohl Benjamin, CFO, reported a transaction classified as exercise at Enliven Therapeutics, Inc. involving 6018.000000 shares for an estimated $89367.30. Reported holdings after the transaction were 44018.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Oct 19, 2026
- Filing date
- Oct 21, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
ELVN price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001882764-26-000009 Common Stock
- Transaction date
- Oct 19, 2026 Filed Oct 21, 2026, 09:53 PM · 2d delay
- Shares
- 6,018 sh $14.85 per share
- Estimated value
- $89.3k Computed from shares × price
- Holdings after
- 44,018 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
0 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
CHIEF FINANCIAL OFFICER
- F1
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
- F2
Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and…
- F3
This transaction was executed in multiple trades at prices ranging from $37.785 to $38.765. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provid…
- F4
The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.
0 other transactions
0 recent txs